Small Dose Interferon Sublingual
Dripping Plus Herbal Remedies -An Experimental Treatment for Chronic
Viral Hepatitis, by Patients
(This article is about
experimentation. Many of my patients have sought to improve the efficacy
of their IFN based treatments by varying the rate and amount of intake.
These changes were made with the cooperation of their physicians. Patients
with chronic viral hepatitis should consult with their physician before
any changes are made to their treatment protocol.)
Interferon is a cytokine,
secreted by the lymph cells, a type of white blood cell.
When a person is infected with a virus, the production of this particular
cytokine increases and becomes an anti-viral weapon of the body. In
addition, IFN also has extensive physiological and immunological effects.
Pharmacological studies showed that interferon has anti-viral,
anti-inflammatory, anti-fibrotic, and anti-cancer effects. All of these
effects are very useful in treating chronic viral hepatitis B and C.
In patients with chronic
viral hepatitis (HBV and HCV), the level of interferon (IFN) gradually
becomes depleted. This is one of the reasons why an acute infection
develops into a chronic infection. Thus, supplementing the body with IFN
to enhance its anti-viral defense is the main therapeutic method of
conventional medicine. IFN-based
treatments are now available in different several forms: alfa-IFN
solo-therapy, Infergen (Interferon alfacon-1), IFN plus ribavirin
combination therapy, Peg-intron (Peginterferon Alfa-2b) plus ribavirin,
and Pegysis plus ribavirin combination therapies.
Currently, the approximate efficacy rate for sustained response to IFN
based treatments is about 50%. That means about half of patients treated
with these methods reach a viral load of undetectable status six months
after the treatment has finished. The response rate is largely dependent
on the genotype of the HCV, stage of progression, age, and sex of the
patient. The most common genotype, 1a or 1b has the smallest response
rate: around 35%. For genotypes 2 or 3, the response rate is around 66%.
Newer versions if IFN,
such as peg-IFN, is improving the response rate.
However, the side effects can still be quite serious and hard to
tolerate. The side effects are mainly caused by the size of the dose. When
alpha-IFN was used as a mono-therapy or combine with ribavirin as a combination therapy, the dosage was 3 million units, three
intra-muscular injections per week. With
Peg-intron and Pegysis, the once-a-week injection dose remained at 3
million units, the only difference being the frequency of intake was
reduced to once a week. The purpose was to release the Peg-IFN slowly
overtime. The main problem again, was the large size of the dose, which
continued to cause intolerable side-effects for many patients. Many of
these patients suggested using lower and more frequent doses to their
doctors and some agreed to the experiment.
The description below
is a report of the progress these patients have made. It is purely for
informational purposes and is not a substitute for medical advise.
With the cooperation
of their respective physicians, the daily dose starts from 300,000 units
(1/10 of the one injection dose in the evening) and slowly builds the
tolerance level to eventually reach 600,000 units (one dose in the evening
and one in the morning).
The old version of IFN
is in a solution form, packed in a vial that contains the 3 million units
in 0.5 cc volume. It was divided into 10 drops, one drop contained 300,000
units of the IFN or 1/10 of the original dose.
To start, patients
took one drop sublingually per day. They dripped it under the tongue and
kept it there for at least one minute without swallowing. The mucus
membrane of the mouth absorbed the IFN into the blood stream directly. The
saliva did not destroy it because saliva does not contain any protease.
The dripping was done in the evening, before bed. After a few weeks, the
body built a tolerance and doses were gradually increased to 600,000 units
of IFN. At this stage, most of the patients did not experience any side
effects of IFN. Only a few people found that after the dripping, they felt
slightly discomfort in the local mucus membrane area along with some
For Pegintron, or Pegysis
IFN, both are in powder form. People are experimenting to divide the one
dose powder into 10 small parts. Every day, one part of the powder is
placed under the tongue. With these methods, people are getting the
benefits from IFN without experiencing side effects.
The clinical results
First, almost every
patient saw their ALT, and AST dramatically improved or normalized.
Second, viral load dramatically reduced. Total eradication is still not feasible for many patients but the results
showed reduced liver inflammation and viral replication.
Third, very few
side-effects relative to conventional large-dose IFN treatment.
If used with herbal
remedies, there was dramatic overall improvement of symptoms. Patients who
were not able to tolerate IFN before were able to do so and reap some of
The results have been
positive and I do encourage patients with work with their liver specialist
to find the best treatment route, using variations of conventional
Please keep in mind, this
is a self-designed patient experimentation. There was no
placebo-controlled, randomized, double blinded tests to support its
However, I do think that
this method is rational and the overall clinical results have been